Compare Sanofi SA (SNY) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Sanofi SA trades at $40.66 (market cap $96.38B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $287.3 (market cap $48.39B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.08%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| SNY | WAB | |
|---|---|---|
Market Cap | $96.38B | $48.39B |
Volume | 5,335,342 | 801,560 |
Sector | Health | Industrials |
52-Week High | $52.34 | $305.79 |
52-Week Low | $39.12 | $193.43 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $115.67B | $54.29B |
Dividend Yield | 6.08% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.12, down 1.56% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, potentially driving future growth. Analyst consensus is mixed, with 44% buy ratings but a majority hold stance.
The outlook is cautiously optimistic, supported by earnings beats and strategic partnerships, but risks include a projected net income decline in 2026 and competitive pressures. The stock's current valuation metrics, such as a P/E of 22.06, appear reasonable relative to historical performance, though investor sentiment remains tempered by near-term challenges.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
